# Thymosin alpha-1

Source: https://aminodesk.com/library/thymosin-alpha-1
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Thymosin alpha-1 is an immune-signaling peptide originally found in the thymus. It is sold as a prescription drug, Zadaxin (thymalfasin), in many countries for chronic hepatitis B. It is not FDA-approved, and an FDA advisory committee voted against allowing it to be compounded.

- **Legal lane:** approved outside the US; no lawful US route
- **Evidence grade:** B
- **Form:** injection under the skin
- **Brand abroad:** Zadaxin

## What it is

Thymosin alpha-1 is a 28-amino-acid peptide that influences how T cells mature and respond. The drug version is made synthetically and matches the natural sequence. It is unrelated to [TB-500](https://aminodesk.com/library/tb-500), which comes from a different thymus protein, thymosin beta-4.

## What the evidence shows

Most of the human evidence is in chronic hepatitis B, including randomized trials in Asia and Europe, with mixed results across studies. Clinics in the US promote it for general immune support and recovery, which are not the uses it was tested and approved for.

FDA reviewers evaluated it for hepatitis B, hepatitis C, HIV and other uses in 2024. At the December 2024 advisory committee meeting, members voted 17 to 4 against adding it to the list of substances pharmacies may compound, citing a lack of compelling evidence of effectiveness and safety.

## Dosing where it is approved

The approved hepatitis B regimen abroad is 1.6 mg injected under the skin twice a week, for about six months, under a doctor's care. That is a dose for a specific liver infection. No dose is established for immune support in healthy people.

## Legal status

There is no FDA-approved product, the advisory committee recommended against compounding it, and it is not one of the six peptides covered by the October 2026 HHS policy. Products sold in the US are research chemicals.

## Safety

- It was generally well tolerated in the hepatitis trials.
- Because it is meant to stimulate the immune system, people with autoimmune disease or an organ transplant have particular reason not to use it without a doctor.

## Common questions

### Is thymosin alpha-1 FDA-approved?

No. It is sold abroad as Zadaxin for chronic hepatitis B. In December 2024 an FDA advisory committee voted 17 to 4 against allowing pharmacies to compound it.

### Is thymosin alpha-1 the same as TB-500?

No. They are unrelated. TB-500 comes from a different thymus protein, thymosin beta-4.

### What is the usual thymosin alpha-1 dose?

The approved hepatitis B regimen abroad is 1.6 mg under the skin twice a week for about six months, under a doctor's care. No dose is established for immune support in healthy people.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [FDA briefing document: evaluation of thymosin alpha-1, December 2024 (PDF)](https://www.fda.gov/media/183820/download)
- [FDA: minutes of the December 4, 2024 Pharmacy Compounding Advisory Committee, with votes (PDF)](https://fda.gov/media/185642/download)
- [Iino et al. 2005: thymosin alpha-1 in Japanese patients with chronic hepatitis B (PubMed)](https://pubmed.ncbi.nlm.nih.gov/15914092/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
